GGrantIndex
← Leaderboards

Julie R Park

Children'S Hosp Of Philadelphia

Google Scholar ↗PubMed ↗ORCID ↗
$6,704,912
Attributed
$10,318,555
Total exposure
28
Grants
21
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2M · FY2005–25
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,318,555 · 28

By mechanism

U01$7,227,287 · 1
P01$2,328,974 · 2
K23$656,100 · 1
M01$106,194 · 24

Top collaborators

Most similar at Children'S Hosp Of Philadelphia

Same institution · by research overlap

Others in their field

Top investigators on “Child”

Research focus

ChildClinical ResearchResearch PersonnelRefractoryInstitutionNeuroblastomaResourcesSafetyGrantUnited States National Institutes Of HealthPediatric Neoplasm /CancerClinical TrialsSiteDoseBiologicalCellsHuman SubjectHigh RiskHuman Therapy EvaluationResponsePatient Oriented ResearchProgramsEligibility DeterminationIndustry

Grant awards (47)

Translational, statistical, and clinical trials core$407,869
P01 · FY2025 · CA · contact PI
Translational, statistical, and clinical trials core$676,826
P01 · FY2024 · CA · contact PI
Accelerate cellular immunotherapy development for treatment of life-threatening childhood disorders$1,395,617
U01 · FY2022 · TR · contact PI
Accelerate cellular immunotherapy development for treatment of life-threatening childhood disorders$1,390,827
U01 · FY2021 · TR · contact PI
Clinical Trials and Translation$335,600
P01 · FY2021 · CA · contact PI
Accelerate cellular immunotherapy development for treatment of life-threatening childhood disorders$1,386,496
U01 · FY2020 · TR · contact PI
Clinical Trials and Translation$367,442
P01 · FY2020 · CA · contact PI
Prospective evaluation of barriers to patient referral and enrollment in emerging cellular therapy trials: determining methods and structure to improve equity in future trial design$159,801
U01 · FY2020 · TR · contact PI
Accelerate cellular immunotherapy development for treatment of life-threatening childhood disorders$1,416,172
U01 · FY2019 · TR · contact PI
Clinical Trials and Translation$541,237
P01 · FY2019 · CA · contact PI
Accelerate cellular immunotherapy development for treatment of life-threatening childhood disorders$1,478,374
U01 · FY2018 · TR · contact PI
ADVL0319 PHASE I STUDY OF CC-5013 (LENALIDOMIDE) IN PEDIATRIC PATIENTS$763
M01 · FY2007 · RR · contact PI
COG ADVL0419: VALPROIC ACID IN CHILDREN WITH RECURRENT/PROGRESSIVE SOLID TUMORS$763
M01 · FY2007 · RR · contact PI
COG ADVL0413: A PHASE I STUDY OF THE RAF KINASE AND RECEPTOR TYROSINE KINASE$305
M01 · FY2007 · RR · contact PI
COG ADVL0416: A PHASE 1 STUDY OF SAHA IN PEDIATRIC PATIENTS WITH RECURRENT$153
M01 · FY2007 · RR · contact PI
NANT 2004-01: A PHASE I STUDY OF ZOLEDRONIC ACID (ZOMETA) WITH CYCLOPHOSPHAMIDE$153
M01 · FY2007 · RR · contact PI
NANT 2001-03: PHASE 1 STUDY OF CEP-701 IN PATIENTS WITH REFRACTORY NEUROBLASTOMA$152
M01 · FY2007 · RR · contact PI
NANT 2003-01: A PHASE I STUDY OF ORAL IRINOTECAN, TEMOZOLOMIDE, AND CEFIXIME$77
M01 · FY2007 · RR · contact PI
Novel Therapies for High-Risk Neuroblastoma$131,220
K23 · FY2006 · CA · contact PI
COG ADVL0314: A PHASE 1 STUDY OF BEVACIZUMAB IN REFRACTORY SOLID TUMORS$8,269
M01 · FY2006 · RR · contact PI
COG ADVL0316: A PHASE I STUDY OF 17-AAG IN RELAPSED/REFRACTORY PEDIATRIC$4,621
M01 · FY2006 · RR · contact PI
NANT 2002-01 PHASE 1 STUDY OF HIGH DOSE PYRASOLACRIDINE (PZA)(NSC 366140) SUPPOR$3,307
M01 · FY2006 · RR · contact PI
COG ADVL0416: A STUDY OF SAHA IN PEDIATRIC PATIENTS WTH RECURRENT SOLID TUMORS$2,481
M01 · FY2006 · RR · contact PI
NANT 2003-01: A PHASE I STUDY OF ORAL IRINOTECAN, TEMOZOLOMIDE, AND CEFIXIME$2,481
M01 · FY2006 · RR · contact PI
COG ADVL0214: A PHASE I STUDY OF SINGLE AGENT OSI-774 (TARCEVA)$2,481
M01 · FY2006 · RR · contact PI
NANT 2004-01: A PHASE I STUDY OF ZOLEDRONIC ACID (ZOMETA) WITH CYCLOPHOSPHAMIDE$2,481
M01 · FY2006 · RR · contact PI
NANT 2001-03: PHASE 1 STUDY OF CEP-701 IN PATIENTS WITH REFRACTORY NEUROBLASTOMA$1,655
M01 · FY2006 · RR · contact PI
COG ADVL0317: A PHASE I STUDY OF PS-341 (VELCADE, BORTEZOMIV) IN PED PATIENTS$1,655
M01 · FY2006 · RR · contact PI
ADVL0319 PHASE I STUDY OF CC-5013 (LENALIDOMIDE) IN PEDIATRIC PATIENTS$826
M01 · FY2006 · RR · contact PI
Novel Therapies for High-Risk Neuroblastoma$131,220
K23 · FY2005 · CA
COG-ANBL02P1: A PILOT INDUCTION REGIMEN INCORPORATING TOPOTECAN FOR TREATMENT O$16,403
M01 · FY2005 · RR
COG ADVL0211: G3139 WITH CYTOTOXIC CHEMOTHERAPY IN RELAPSED CHILDHOOD TUMORS$6,418
M01 · FY2005 · RR
COG ADVL0215: DECITABINE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE$4,279
M01 · FY2005 · RR
COG ADVL0314: A PHASE 1 STUDY OF BEVACIZUMAB IN REFRACTORY SOLID TUMORS$2,852
M01 · FY2005 · RR
COG ADVL0316: 17-AAG IN PEDIATRIC PATIENTS WITH SOLID TUMORS OR LEUKEMIA$1,427
M01 · FY2005 · RR
COG-ADVL0311: PEMETREXED IN CHILDREN AND ADOLESCENTS WITH RECURRENT SOLID TUMORS$712
M01 · FY2005 · RR
NANT 2001-03: PHASE 1 STUDY OF CEP-701 IN PATIENTS WITH REFRACTORY NEUROBLASTOMA$712
M01 · FY2005 · RR
Novel Therapies for High-Risk Neuroblastoma$131,220
K23 · FY2004 · CA
COG ADVL0211 - A Phase I Trial of G3139 (BCL-2 Antisense, NSC# 683428, IND# 588s$15,614
M01 · FY2004 · RR
CCG-A0981, A Phase I Intergroup Trial of the HU14.18-IL2 Fusion Protein in Chils$10,843
M01 · FY2004 · RR
COG ADVL0212 - A Phase I Study of Depsipeptide (NSC # 630176, IND # 51810) in Ps$8,240
M01 · FY2004 · RR
COG-ANBL0321: A Phase II Study of Fenretinide (NSC #374551, IND #40294) in Chia$3,036
M01 · FY2004 · RR
NANT 2002-01 Phase 1 Study of High Dose Pyrasolacridine (PZA)(NSC 366140) Suppor$1,734
M01 · FY2004 · RR
NANT 2001-03: Phase 1 Study of CEP-701 in patients with Refractory Neuroblastoma$868
M01 · FY2004 · RR
COG ADVL0215: A phase I Study of Decitabine (NSC #127716, IND #50733) in Combin$433
M01 · FY2004 · RR
Novel Therapies for High-Risk Neuroblastoma$131,220
K23 · FY2003 · CA
Novel Therapies for High-Risk Neuroblastoma$131,220
K23 · FY2002 · CA